News & Updates

A pharmacy-specific, foundational HIV management education package can help improve pharmacist knowledge in HIV management and self-reported confidence in managing this specialty area, suggests a recent study.

A new patient achieves sustained HIV remission – the seventh in the world – following stem cell therapy for blood cancer and after stopping antiretroviral therapy (ART), adding to the roster of individuals with HIV who are inching their way towards a potential cure.

Pre-exposure prophylaxis (PrEP) with the antibiotic doxycycline helps to prevent sexually transmitted infections (STIs) in high-risk populations, including female sex workers and HIV-positive men who have sex with men (MSM), according to two small studies.

Virally suppressed adolescents living with HIV-1 who switched from daily oral to long-acting (LA) injectable cabotegravir (CAB) plus rilpivirine (RPV) every 8 weeks show an acceptable safety profile, with pharmacokinetics similar to adults, according to the week-48 results of the IMPAACT 2017 study.

New drug applications approved by US FDA as of 16-31 July 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

A study compared mortality rates from COVID-19 and influenza hospitalizations during fall-winter 2023-2024.¹